# Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Source: https://onco.cc/trials/nct04536675/  
OnCo record `nct04536675` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Samsung Medical Center, active but no longer recruiting.

## Summary

Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery is a phase 3, randomised interventional study registered as NCT04536675 by Samsung Medical Center, with a registry enrolment figure of 204 participants, started 2021-04-01 and due to reach its primary completion in 2026-04-03. Interventions recorded: Vilanterol and Umeclidinium Bromide; Placebo. Conditions listed: Chronic Obstructive Pulmonary Disease; Non Small Cell Lung Cancer. Primary outcome: Difference in post-bronchodilator FEV1 between baseline and 16 weeks post-surgery. Lung eligibility wording from the registry: "* Subjects of men or female over 40 years of age who are scheduled for curative pulmonary lobectomy due to confirmation (or high suspicion) of non-small cell lung cancer (NSCLC)". Sites: South Korea. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04536675
- Phase: 3
- Setting: Effect of Perioperative Fixed-dose Dual Bronchodilator Therapy on Post-operative Pulmonary Function Among Mild- to -Moderate COPD Patients Undergoing Lung Cancer Surgery
- Sponsor: Samsung Medical Center
- Enrolled: 204

## Sources

- ClinicalTrials.gov NCT04536675: https://clinicaltrials.gov/study/NCT04536675

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04536675.json